FOLH1 and adenocarcinoma: Standard imaging approaches, such as 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET), thus far do not reliably distinguish SCNC from the more common adenocarcinomas [9] and SCNC is typically negative on a prostate-specific membrane antigen (PSMA) PET [10].